Skip to main content
. Author manuscript; available in PMC: 2012 Aug 18.
Published in final edited form as: Pharmacopsychiatry. 2008 Mar;41(2):48–53. doi: 10.1055/s-2007-993211

Figure 3.

Figure 3

(a) Serum content of the endocannabinoid N-arachidonylethanolamine (anandamide; AEA) exhibited a significant negative correlation (r = −.647) with Hamilton ratings for cognitive anxiety.

(b) Serum content of the endocannabinoid AEA exhibited a significant negative correlation (r = −.674) with Hamilton ratings for somatic anxiety.